Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04421339 · ClinicalTrials.gov registry record · NA
Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study
A NA study of Huntington Disease, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04421339: Completed NA study of Huntington Disease, sponsored by The University of Texas Health Science Center, Houston.
NCT04421339 is a NA study of Huntington Disease that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 15 participants, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04421339, a NA study of Huntington Disease, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the efficacy of exogenous melatonin in improving sleep quality in HD gene carriers.
Primary Outcome
The PSQI is a 9-question instrument used to measure the quality and patterns of sleep in adults. Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. A global sum of "5"or greater indicates a "poor" sleeper.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Melatonin
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-01-22 |
| Est. Completion | 2022-09-16 |
| Phase | NA |
What the finished NCT04421339 record still lists
NCT04421339 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04421339 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04421339 about?
NCT04421339 is a clinical study titled "Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study". The purpose of the study is to evaluate the efficacy of exogenous melatonin in improving sleep quality in HD gene carriers.
What is the current status of trial NCT04421339?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2021-01-22. Estimated completion is 2022-09-16.
What conditions does trial NCT04421339 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT04421339?
The interventions under investigation include: Placebo (OTHER), Melatonin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04421339?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04421339 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04421339's enrollment target sits among peer trials
15 33rd of 35 higher than 3 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease
RECRUITING · NA
-
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
RECRUITING · NA
-
Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease
RECRUITING · NA
-
Move to Improve: Telehealth Exercise to Music for HD
COMPLETED · NA
-
Time-Restricted Eating in Huntington's Disease: A Clinical Pilot Study
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI